Loading
VIPER-102 is an experimental CAR-T cell therapy from Vittoria Biotherapeutics, in preclinical development for solid tumours.
VIPER-102 is a CAR-T cell therapy from Vittoria Biotherapeutics. CAR T cells against an undisclosed solid tumour antigen that the company says is over-expressed by malignant cells and compartmentalised in healthy tissue. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. IND-enabling studies per pipeline page. It has not been shown to work in people.
CAR T cells against an undisclosed solid tumour antigen that the company says is over-expressed by malignant cells and compartmentalised in healthy tissue.
1.VIPER-102 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VIPER-102" OR ABSTRACT:"VIPER-102") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VIPER-102, not a curated reading list.
Shares Vittoria Biotherapeutics and the tag pipeline.
Shares Vittoria Biotherapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/